ALLIANT Pharmaceuticals, Inc. Signs Co-Promotion Agreement With Sanofi-Aventis (France) For Allegra(R) (fexofenadine hydrochloride) Oral Suspension
"Our core mission is to provide pediatricians with alternatives that meet the unique needs of their patients," said Mark Pugh, President of Alliant. "We are excited to enter this agreement with sanofi-aventis on Allegra Oral Suspension so we may offer a new treatment option for this pediatric population."
Sanofi-aventis received FDA approval for Allegra Oral Suspension in October 2006 for the relief of symptoms associated with seasonal allergies in pediatric patients, 2 to 11 years of age, and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years of age.
Important Safety Information
Side effects in children 6 months to 5 years old were similar to placebo. Side effects varied by age. The most commonly reported side effects were: vomiting, pyrexia, cough, otitis media and diarrhea.
Please see full prescribing information for Allegra Oral Suspension at http://products.sanofi-aventis.us/allegra_oral/allegra.pdf
About Alliant Pharmaceuticals, Inc.
Alliant Pharmaceuticals, Inc. is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products to pediatricians and pediatric specialty physicians. Alliant Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. Additional information about Alliant Pharmaceuticals is available online at: http://www.alliantpharma.com.
Contact: Sharon Kraun
Tel: 404.961.2242 skraun@co-p.com
Source: Alliant Pharmaceuticals, Inc.